Unknown

Dataset Information

0

Antibody-induced erythrophagocyte reprogramming of Kupffer cells prevents anti-CD40 cancer immunotherapy-associated liver toxicity.


ABSTRACT:

Background

Agonistic anti-CD40 monoclonal antibodies (mAbs) have emerged as promising immunotherapeutic compounds with impressive antitumor effects in mouse models. However, preclinical and clinical studies faced dose-limiting toxicities mediated by necroinflammatory liver disease. An effective prophylactic treatment for liver immune-related adverse events that does not suppress specific antitumor immunity remains to be found.

Methods

We used different mouse models and time-resolved single-cell RNA-sequencing to characterize the pathogenesis of anti-CD40 mAb induced liver toxicity. Subsequently, we developed an antibody-based treatment protocol to selectively target red blood cells (RBCs) for erythrophagocytosis in the liver, inducing an anti-inflammatory liver macrophage reprogramming.

Results

We discovered that CD40 signaling in Clec4f+ Kupffer cells is the non-redundant trigger of anti-CD40 mAb-induced liver toxicity. Taking advantage of the highly specific functionality of liver macrophages to clear antibody-tagged RBCs from the blood, we hypothesized that controlled erythrophagocytosis and the linked anti-inflammatory signaling by the endogenous metabolite heme could be exploited to reprogram liver macrophages selectively. Repeated low-dose administration of a recombinant murine Ter119 antibody directed RBCs for selective phagocytosis in the liver and skewed the phenotype of liver macrophages into a Hmoxhigh/Marcohigh/MHCIIlow anti-inflammatory phenotype. This unique mode of action prevented necroinflammatory liver disease following high-dose administration of anti-CD40 mAbs. In contrast, extrahepatic inflammation, antigen-specific immunity, and antitumor activity remained unaffected in Ter119 treated animals.

Conclusions

Our study offers a targeted approach to uncouple CD40-augmented antitumor immunity in peripheral tissues from harmful inflammatoxicity in the liver.

SUBMITTER: Pfefferle M 

PROVIDER: S-EPMC9809320 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Antibody-induced erythrophagocyte reprogramming of Kupffer cells prevents anti-CD40 cancer immunotherapy-associated liver toxicity.

Pfefferlé Marc M   Dubach Irina L IL   Buzzi Raphael M RM   Dürst Elena E   Schulthess-Lutz Nadja N   Baselgia Livio L   Hansen Kerstin K   Imhof Larissa L   Koernig Sandra S   Le Roy Didier D   Roger Thierry T   Humar Rok R   Schaer Dominik J DJ   Vallelian Florence F  

Journal for immunotherapy of cancer 20230101 1


<h4>Background</h4>Agonistic anti-CD40 monoclonal antibodies (mAbs) have emerged as promising immunotherapeutic compounds with impressive antitumor effects in mouse models. However, preclinical and clinical studies faced dose-limiting toxicities mediated by necroinflammatory liver disease. An effective prophylactic treatment for liver immune-related adverse events that does not suppress specific antitumor immunity remains to be found.<h4>Methods</h4>We used different mouse models and time-resolv  ...[more]

Similar Datasets

2022-11-09 | GSE202918 | GEO
| S-EPMC8845079 | biostudies-literature
2022-11-09 | GSE202916 | GEO
| S-EPMC8149790 | biostudies-literature
2022-11-09 | GSE202917 | GEO
2021-09-08 | GSE156160 | GEO
| S-EPMC7973783 | biostudies-literature
2021-06-04 | GSE176109 | GEO
2021-06-03 | GSE175737 | GEO
| S-EPMC6955310 | biostudies-literature